Cipla and major Indian pharmaceutical shares fell up to 2.5% on July 22, 2026.
US President Donald Trump announced plans for 100-200% tariffs on imported generic drugs. These tariffs are scheduled to take effect in 2028.
The US market remains a primary revenue source for Cipla's generic drug exports. Investors expressed concern over the future profitability of Indian exporters following the announcement.
Cipla reported a significant annual bottom-line drop for the 2026 fiscal year. The company also recorded a sequential decline in its most recent quarterly profit.
Cipla's board will meet on July 23, 2026, to discuss Q1 FY27 results.